Seegene Unveils a Game-Changing Automated PCR Solution CURECA™ for the Future of Diagnostics
In a significant advancement for molecular diagnostics, Seegene Inc., a global leader in microbiological diagnostics, has unveiled CURECA™, a next-generation fully automated PCR (Polymerase Chain Reaction) solution. This innovative system was spotlighted during the recent ESCMID Global 2025 event held in Vienna, Austria. CURECA™ is designed to transform the automation of PCR testing by enabling customizable and full automation of the workflow, from sample pre-processing to result analysis, thereby reinforcing Seegene's commitment to leading laboratory automation innovation.
Seegene's CURECA™ is crafted not only to fulfill the laboratory's needs for high-throughput and efficient PCR testing, but also to align with the company's overarching vision of creating a world free from diseases. The name CURECA is an acronym for Continuous Unlimited Random access Expandable and Customizable full Automation, reflecting its design philosophy aimed at eliminating human error risks and promoting a seamless, 24/7 testing operation.
The system comprises two key components: the Customizable Preprocessing System (CPS) and the Customizable Expandable Fully Automated system (CEFA). The CPS is tasked with the crucial role of sample loading and pre-processing management, whereas CEFA oversees sample loading, nucleic acid extraction, PCR setup, gene amplification, and result analysis. This design aims to automate not just PCR testing but also other laboratory testing environments, enhancing the versatility and utility of the system across various medical and clinical applications.
Traditionally, manual labor by skilled technicians has been necessary to manage the preprocessing steps of diverse sample types, such as stool, urine, blood, and sputum. Seegene aims to alleviate the burden of this manual work through CPS, which automates vital processes like sample sorting, centrifugation, vortexing, and thermal treatment. Importantly, CPS can operate independently of the complete CURECA™ system, allowing it to be adapted for use in hematology, biochemistry, and immunodiagnostic tests.
At the ESCMID Global 2025, an informative concept video was showcased, illustrating CURECA™'s comprehensive workflow from sample loading to results analysis. During this virtual presentation, Seegene showcased how the system can adapt to various laboratory environments and enhance testing workflows. The upcoming demonstration of the physical system is scheduled for July 2025 during the Association for Diagnostic Medical and Laboratory (ADLM 2025) conference in Chicago.
CURECA™ supports Seegene’s mission to redefine the standards of molecular diagnostics. Dr. Jong-Yoon Chun, founder and CEO of Seegene, emphasized the significance of this innovation, stating, "Until now, there was no existing system capable of fully automating the preprocessing management of all sample types, which hindered true automation in MDx." He expressed a commitment to shaping the future of MDx through innovation and collaboration, reinforcing the necessity of rapidly accessible molecular diagnostics integrated into daily healthcare.
The newly introduced CURECA™ also aligns with the growing concerns of antimicrobial resistance (AMR) and the evolving needs for diagnostics in the post-COVID-19 era. During the ESCMID event, Seegene presented its real-time syndromic PCR testing portfolio, addressing AMR alongside the rising therapeutic decision-making challenges and diagnostics requirements.
In this context, Seegene's testing solutions, such as Entero DR for drug resistance and STI-AMR for sexually transmitted infections, are poised to deliver more timely and informed treatment decisions, ultimately contributing to improved patient outcomes.
With over two decades of research, development, and production experience in real-time syndromic PCR technologies, Seegene has been pivotal, especially during the COVID-19 pandemic, supplying over 340 million tests globally. The innovative platform allows testing of up to 14 pathogens in a single tube, demonstrating unmatched testing efficiency and accuracy.
Overall, CURECA™ is not just a technological leap; it symbolizes a global call to action for enhanced healthcare diagnostics, aiming at an ambitious goal: a world liberated from infectious diseases and wellness for human and animal health alike. Seegene's collaborative initiatives on technology sharing, especially in co-developing diagnostics that address local healthcare needs, further illustrate their commitment to this vision. For more information, visit Seegene’s website.
The Vision Behind CURECA™
Seegene's CURECA™ is crafted not only to fulfill the laboratory's needs for high-throughput and efficient PCR testing, but also to align with the company's overarching vision of creating a world free from diseases. The name CURECA is an acronym for Continuous Unlimited Random access Expandable and Customizable full Automation, reflecting its design philosophy aimed at eliminating human error risks and promoting a seamless, 24/7 testing operation.
Automation Features
The system comprises two key components: the Customizable Preprocessing System (CPS) and the Customizable Expandable Fully Automated system (CEFA). The CPS is tasked with the crucial role of sample loading and pre-processing management, whereas CEFA oversees sample loading, nucleic acid extraction, PCR setup, gene amplification, and result analysis. This design aims to automate not just PCR testing but also other laboratory testing environments, enhancing the versatility and utility of the system across various medical and clinical applications.
Traditionally, manual labor by skilled technicians has been necessary to manage the preprocessing steps of diverse sample types, such as stool, urine, blood, and sputum. Seegene aims to alleviate the burden of this manual work through CPS, which automates vital processes like sample sorting, centrifugation, vortexing, and thermal treatment. Importantly, CPS can operate independently of the complete CURECA™ system, allowing it to be adapted for use in hematology, biochemistry, and immunodiagnostic tests.
Promoting Global Health
At the ESCMID Global 2025, an informative concept video was showcased, illustrating CURECA™'s comprehensive workflow from sample loading to results analysis. During this virtual presentation, Seegene showcased how the system can adapt to various laboratory environments and enhance testing workflows. The upcoming demonstration of the physical system is scheduled for July 2025 during the Association for Diagnostic Medical and Laboratory (ADLM 2025) conference in Chicago.
CURECA™ supports Seegene’s mission to redefine the standards of molecular diagnostics. Dr. Jong-Yoon Chun, founder and CEO of Seegene, emphasized the significance of this innovation, stating, "Until now, there was no existing system capable of fully automating the preprocessing management of all sample types, which hindered true automation in MDx." He expressed a commitment to shaping the future of MDx through innovation and collaboration, reinforcing the necessity of rapidly accessible molecular diagnostics integrated into daily healthcare.
Addressing Antimicrobial Resistance
The newly introduced CURECA™ also aligns with the growing concerns of antimicrobial resistance (AMR) and the evolving needs for diagnostics in the post-COVID-19 era. During the ESCMID event, Seegene presented its real-time syndromic PCR testing portfolio, addressing AMR alongside the rising therapeutic decision-making challenges and diagnostics requirements.
In this context, Seegene's testing solutions, such as Entero DR for drug resistance and STI-AMR for sexually transmitted infections, are poised to deliver more timely and informed treatment decisions, ultimately contributing to improved patient outcomes.
About Seegene
With over two decades of research, development, and production experience in real-time syndromic PCR technologies, Seegene has been pivotal, especially during the COVID-19 pandemic, supplying over 340 million tests globally. The innovative platform allows testing of up to 14 pathogens in a single tube, demonstrating unmatched testing efficiency and accuracy.
Overall, CURECA™ is not just a technological leap; it symbolizes a global call to action for enhanced healthcare diagnostics, aiming at an ambitious goal: a world liberated from infectious diseases and wellness for human and animal health alike. Seegene's collaborative initiatives on technology sharing, especially in co-developing diagnostics that address local healthcare needs, further illustrate their commitment to this vision. For more information, visit Seegene’s website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.